- Email: [email protected]
Correction to Lancet Diabetes Endocrinol 2015; 3: 931
Corrections
Correction to Lancet Correction to Lancet Diabetes Endocrinol 2015; Diabetes Endocrinol 3: 931 2015; 3: 925–27 Naciemail H, Basu S, Yudkin JS. Preventing cardiovascular events with empagliflozin: at what cost? Lancet Diabetes Endocrinol 2015; 3: 931— The last sentence in paragraph four should read “For example, metaanalyses of interventional studies did not detect any benefits of intensive glucose lowering on cerebrovascular disease, despite the epidemiological association between levels of glycaemia and stroke”. This correction has been made to the online version as of Nov 25, 2015.
Correction to Lancet Diabetes Endocrinol 2015; 3: 925–27 Gifford R, Siribaddana S, Forbes S, Eddleston M. Endocrine-disrupting chemicals and the diabetes epidemic in countries in the WHO South-East Asia region. Lancet Diabetes Endocrinol 2015; 3: 925–27—The figure in this Comment has been corrected. This correction has been made to the online version as of Nov 25, 2015.
Gifford R, Siribaddana S, Forbes S, Eddleston M. Endocrine-disrupting chemicals and the diabetes epidemic in countries in the WHO South-East Asia region. Lancet Diabetes Endocrinol 2015; 3: 925–27—An uncited reference has been deleted, the order of the remaining references has been updated, and the appendix has been added. These corrections have been made to the online version as of Dec 4, 2015.
Published Online November 25, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00464-7 Published Online December 4, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00473-8
Correction to Lancet Diabetes Endocrinol 2015; 3: 758–60 Luthra A, Misra A. The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol 2015; 3: 758–60—In this Comment, the final sentence in the sixth paragraph should have read “Hydroxychloroquine was approved in India as an adjunct to lifestyle management and combined sulphonylureas and metformin in patients with diabetes on Jan 15, 2015.” This correction has been made to the online version as of Dec 8, 2015.
Published Online December 8, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00481-7 Published Online November 25, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00463-5
Figure: Countries in the WHO South-East Asia region
www.thelancet.com/diabetes-endocrinology Vol 4 January 2016
e1
Correction to Lancet Correction to Lancet Diabetes Endocrinol 2015; Diabetes Endocrinol 3: 931 2015; 3: 925–27 Naciemail H, Basu S, Yudkin JS. Preventing cardiovascular events with empagliflozin: at what cost? Lancet Diabetes Endocrinol 2015; 3: 931— The last sentence in paragraph four should read “For example, metaanalyses of interventional studies did not detect any benefits of intensive glucose lowering on cerebrovascular disease, despite the epidemiological association between levels of glycaemia and stroke”. This correction has been made to the online version as of Nov 25, 2015.
Correction to Lancet Diabetes Endocrinol 2015; 3: 925–27 Gifford R, Siribaddana S, Forbes S, Eddleston M. Endocrine-disrupting chemicals and the diabetes epidemic in countries in the WHO South-East Asia region. Lancet Diabetes Endocrinol 2015; 3: 925–27—The figure in this Comment has been corrected. This correction has been made to the online version as of Nov 25, 2015.
Gifford R, Siribaddana S, Forbes S, Eddleston M. Endocrine-disrupting chemicals and the diabetes epidemic in countries in the WHO South-East Asia region. Lancet Diabetes Endocrinol 2015; 3: 925–27—An uncited reference has been deleted, the order of the remaining references has been updated, and the appendix has been added. These corrections have been made to the online version as of Dec 4, 2015.
Published Online November 25, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00464-7 Published Online December 4, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00473-8
Correction to Lancet Diabetes Endocrinol 2015; 3: 758–60 Luthra A, Misra A. The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol 2015; 3: 758–60—In this Comment, the final sentence in the sixth paragraph should have read “Hydroxychloroquine was approved in India as an adjunct to lifestyle management and combined sulphonylureas and metformin in patients with diabetes on Jan 15, 2015.” This correction has been made to the online version as of Dec 8, 2015.
Published Online December 8, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00481-7 Published Online November 25, 2015 http://dx.doi.org/10.1016/ S2213-8587(15)00463-5
Figure: Countries in the WHO South-East Asia region
www.thelancet.com/diabetes-endocrinology Vol 4 January 2016
e1